tiprankstipranks
Perrigo reports FY22 EPS (97c) vs. (98c) last year
The Fly

Perrigo reports FY22 EPS (97c) vs. (98c) last year

Reports FY22 revenue $4.45B vs. $4.14B last year. CEO Murray Kessler commented, "Perrigo completed its transformation from a healthcare company to a pure play consumer self-care company early in 2022 with the closing of the HRA Pharma acquisition. And it was from the momentum that was created through this transformation that the Company was able to deliver constant currency double-digit top-line and adjusted bottom-line growth in 2022, including all-time net sales records for both our Americas and International businesses, a 500 basis point recovery in adjusted gross margin from the first quarter to the fourth, continued market share gains across the portfolio, and cash conversion of over 100%. Perrigo’s strong year came behind an exceptionally strong fourth quarter that achieved 10% constant currency net sales growth and 33% constant currency adjusted diluted EPS growth along with adjusted gross margin up over 350 basis points versus year ago! I am so proud of how my Perrigo colleagues delivered these results, while at the same time navigating through unprecedented global supply chain disruptions, labor shortages, broad-based inflation, the Russia-Ukraine war, the infant formula shortage, and the continuing impact of the Covid-19 pandemic. It’s a testament to the resiliency and nimbleness of the new Perrigo Consumer Self-Care Company."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on PRGO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles